AlphAIalphai — Financial news for AI agents
finanznachrichten.deAUG 136 min read$ENSC

Ensysce Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Ensysce Biosciences (NASDAQ:ENSC) reported Q2 2026 results and said it completed its Cy Biopharma acquisition on Aug. 6, adding CY200 for CRPS Type 1. The deal used $38.6M private placement funding and a stock-for-stock merger, with about $21.5M gross preferred proceeds. Cash fell to $0.7M at June 30; net loss was $2.6M.

Original reporting
finanznachrichten.de
Published Aug 13, 2026, 8:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 13, 2026, 9:13 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefMergers & acquisitions
Primary signal
$ENSC
Bullish
medium confidence
Mentioned
$ENSC
Relevance
8/10
alphai data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$ENSCBullishMed
01

Why it matters

The completed Cy Biopharma acquisition adds an Orphan Drug-designated CRPS candidate (CY200) and is paired with a sizable private placement and grant-supported clinical activity, extending runway and reshaping the pipeline risk profile.

02

Market read

Traders can reassess Ensysce’s funding runway, pipeline composition, and near-term catalyst calendar ahead of the Aug 18 corporate update call.

03

What to watch

The second financing tranche is milestone-triggered (up to $38.6M), so the market may discount how likely and how soon those milestones are achieved; also, the article provides limited detail on Phase 2 trial design outcomes beyond intent.

Relevance 8/10Novelty 8/10Timing: after-hours disclosure; corporate update call scheduled Aug 18, 2026

Background

Ensysce is a clinical-stage biotech focused on neuroplastogenic therapies for complex pain and opioid abuse-deterrent/overdose-protection technologies.

Company-level read

Ticker impact

$ENSCBullishMedium confidence
Context

Ensysce completed the Cy Biopharma acquisition, adding CY200 for CRPS and announcing a concurrent private placement plus grant-funded opioid program progress.

Expected impact

Near-term bias higher on deal/financing clarity, with volatility tied to cash burn, milestone-triggered tranche timing, and Phase 2/3 execution.

Evidence & confidence

The article discloses a completed acquisition, specific financing sizes, cash runway into late 2027, and updated clinical/IP milestones, which are actionable for positioning in a clinical-stage biotech.

Market effects

Sector

Reinforces investor appetite for neuroplastogenic pain and abuse-deterrent opioid platforms, but highlights ongoing reliance on dilutive private placements and milestone financing.

Regional

Limited direct regional spillover; Taiwan patent extension is a minor IP signal for the opioid abuse-deterrent franchise.

Global

Primarily US biotech-specific; FDA orphan designation and Breakthrough Therapy status are globally relevant for development expectations.

Counterpoint

What could challenge this read

Cash at June 30 was only $0.7M, so despite the post-close funding, the stock may still trade like a dilution story until clinical milestones de-risk CY200 and PF614 programs.

Key entities

  • company
    Ensysce Biosciences, Inc.

    NASDAQ-listed clinical-stage biotech; completed Cy Biopharma acquisition and reported Q2 2026 results and financing.

  • company
    Cy Biopharma, Inc.

    Acquired entity whose CY200 candidate for CRPS Type 1 is added to Ensysce’s lead pipeline.

  • drug_candidate
    CY200

    Orphan Drug-designated neuroplastogenic candidate for CRPS Type 1 added via the Cy Biopharma acquisition.

  • drug_program
    PF614-MPAR

    Combination opioid abuse protection and oral overdose protection program with FDA Breakthrough Therapy designation.

  • clinical_trial
    PF614-301

    Pivotal Phase 3 trial evaluating PF614 for moderate to severe pain following abdominoplasty.

Read at source← All news

Related articles

AUG 13
$ENSCMed

Ensysce Biosciences, Inc. (ENSC): Results of Operations and Financial Condition

Ensysce Biosciences, Inc. (ENSC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Ensysce Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights ~ Acquisition of Cy Biopharma Completed, Adding CY200 for Complex Regional Pain Syndrome ~ ~ Up to $77 million in new funding with the acquis

SEC EDGAR 8-K6 min
AUG 7
$ENSCMedAI 8/10

Ensysce Biosciences Completes Cy Biopharma Acquisition and Secures Up to $77 Million Private Financing

Ensysce Biosciences (NASDAQ:ENSC) completed its acquisition of Cy Biopharma, adding clinical-stage pain drug CY200 for Complex Regional Pain Syndrome with FDA Orphan Drug Designation. Ensysce secured up to $77 million via cash contribution, private placement, and milestone funding. Cy Biopharma shareholders are expected to own about 74.94% after preferred conversion.

yahoo.com5 min
AUG 6
$ENSCMed

Ensysce Biosciences, Inc. (ENSC): Completion of Acquisition or Disposition of Assets

Ensysce Biosciences, Inc. (ENSC) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. EX-2.1 2 ex2-1.htm EX-2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among: ensysce biosciences, Inc., a Delaware corporation; PHRMA MERGER SUB I, INC., a Delaware corporation; PHRMA MERGER SUB II, LLC, a Delaware limited liability company; and Cy Biopharma, Inc., a Delaware

SEC EDGAR 8-K6 min
MAY 28
$ENSCMedAI 9/10

Ensysce Biosciences, Inc. (NASDAQ:ENSC) Short Interest Update

Ensysce Biosciences (NASDAQ:ENSC) reported a sharp rise in short interest: 814,605 shares as of May 15, up from 52,730 on April 30, with about 5.7% of shares sold short and a days-to-cover ratio of 0.1 (based on average daily volume). The stock traded at $0.30. The company reported May 15 quarterly EPS of -$0.52 and revenue of $0.96M.

dailypolitical.com2 min
AUG 13
$ETORMedAI 8/10

eToro aims to boost US profile in $231M TradeZero deal

eToro will acquire U.S. online brokerage TradeZero in a $231 million deal expected to close in H1 2027, according to the companies. eToro said the price includes cash and up to 2.5 million newly issued Class A shares. TradeZero generated about $80 million revenue in the year to June 30. eToro expects accretion to adjusted EPS in the first year post-close.

yahoo.com3 min